Encouraged by the long‐term inhibitory effect of Gel@PCZ on EGFR endocytosis in vivo, we conducted in vivo experiments to determine whether the combined local delivery of PCZ and cetuximab (Gel@Cmab/PCZ) enhances tumor suppression compared with cetuximab alone (Gel@Cmab) or the free drug. The gene discussed is EGFR; the disease is neoplasm.